Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 19INDUSTRY 12OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 4Carcinoma, Hepatocellular 4Esophageal Neoplasms 3Nasopharyngeal Carcinoma 2Immunotherapy 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2SCLC, Extensive Stage 1Mid-low Rectal Cancer 1Melanoma 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Immunotherapy Gastrict Cancer 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Advanced Non-small-cell Lung Cancer 1

Interventions

Irinotecan 11Oxaliplatin 8Cetuximab 7Fluorouracil 6Leucovorin 5Bevacizumab 5Standard of Care 4S 1 (combination) 4Capecitabine 4trifluridine tipiracil drug combination 2tislelizumab 2apatinib 2Propranolol 2Preoperative Exercise 2Panitumumab 2Levoleucovorin 2Folfox protocol 2Etodolac 2Endoscopic Mucosal Resection 2Drug Therapy 2Chemotherapy, Adjuvant 2trebananib 1regorafenib 1envafolimab 1Trifluridine 1Thalidomide 1Surveys and Questionnaires 1Occult Blood 1Neoadjuvant Therapy 1Moxibustion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Colorectal Neoplasms × tislelizumab × Clear all
NCT05799443 2023-04-05

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Fujian Cancer Hospital

Phase 2 Unknown
23 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05314101 2022-08-23

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Fujian Cancer Hospital

Phase 2 Unknown
25 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡